6 Undervalued Biotechnology & Medical Research Stocks for Friday, May 31
Discover the top 6 undervalued Biotechnology & Medical Research stocks for Friday, May 31 based on AAII’s Stock Grades.Eunice Kim
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Commentary & Analysis
Why Adial Pharmaceuticals Inc’s (ADIL) Stock Is Up 128.10%
As of Wednesday, February 28, Adial Pharmaceuticals Inc’s ADIL share price has surged by 128.10%, which has investors questioning if this is right time to sell.Jenna Brashear
Is Adial Pharmaceuticals Inc (ADIL) a Good Investment?
Learn more about Adial Pharmaceuticals Inc’s (ADIL) stock grades for Growth, Momentum and Quality and determine whether this Biotechnology & Medical Research stock meets your investment needs.
Charles Griswold
Financial Summary
| Share Statistics | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $7.2 | $579.1 | 5% |
|
| Shares Out (Mil) | 1.4 | 43.0 | 5% |
|
| Institutional Ownership | 23.5% | 84.3% | 11% |
|
| Float (Mil) | 1.3 | 46.8 | 3% |
|
| Beta | 1.46 | 0.62 | 81% |
|
| Avg Daily Volume (000s) | 46 | 285 | 27% |
|
| Price Change (52-week) |
(71.8%) | 63.8% | 9% |
|
| Growth | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.7% | na |
|
| Net Income (5yr) | 6.0% | (1.4%) | 48% |
|
| EPS (5yr) | 53.5% | 14.9% | 94 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 15.2% | (14.9%) | 74% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | na | 1 | |
| Current EPS | ($0.825) | na | ($14.250) | |
| Month Ago EPS | ($0.825) | na | ($14.250) | |
| # Rev Up | 1 | na | 1 | |
| # Rev Down | 0 | na | 0 | |
| Three Months Ago EPS | ($1.210) | na | ($2.590) | |
| Year/Year Chg | (44.1%) | na | na | |
| Financials | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $272 | na |
|
| Net Income (TTM) (Mil) | ($8) | ($11) | 31% |
|
| EPS (TTM) | ($8.216) | ($0.500) | 5% |
|
| Operating Cash Flow (TTM) (Mil) | ($7) | ($6) | 23% |
|
| Net Cash Flow (TTM) (Mil) | na | $4 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $7 | 0% |
|
| Enterprise Value (Q1) (Mil) | $1 | $522 | 4% |
|
| Valuation | ADIL | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.36 | 2.73 | 35% |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | ADIL | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 65.9% | na |
|
| Net Margin | na | 0.7% | na |
|
| ROA | (179.1%) | (24.6%) | 2% |
|
| ROE | (265.9%) | (19.7%) | 3% |
|
| Liabilities to Assets | 28.9% | 35.5% | 20% |
|
| F-Score | 2 | 3 | 7% |
|
Adial Pharmaceuticals, Inc. did not pass any screens on 7/31/2026.
